Predictive model of response to tafamidis in hereditary ATTR polyneuropathy
Open Access
- 20 June 2019
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 4 (12)
Abstract
BACKGROUND: The hereditary transthyretin (TTR) amyloidoses are a group of diseases for which several disease-modifying treatments are now available. Long-term effectiveness of these therapies is not yet fully known. Moreover, the existence of alternative therapies has resulted in an urgent need to identify patient characteristics that predict response to each therapy. METHODS: We carried out a retrospective cohort study of 210 patients with hereditary TTR amyloidosis treated with the kinetic stabilizer tafamidis (20 mg qd). These patients were followed for a period of 18–66 months, after which they were classified by an expert as responders, partial responders, or nonresponders. Correlations between baseline demographic and clinical characteristics, as well as plasma biomarkers and response to therapy, were investigated. RESULTS: 34% of patients exhibited an almost complete arrest of disease progression (classified by an expert as responders); 36% had a partial to complete arrest in progression of some but not all disease components (partial responders); whereas the remaining 30% continued progressing despite therapy (nonresponders). We determined that disease severity, sex, and native TTR concentration at the outset of treatment were the most relevant predictors of response to tafamidis. Plasma tafamidis concentration after 12 months of therapy was also a predictor of response for male patients. Using these variables, we built a model to predict responsiveness to tafamidis. CONCLUSION: Our study indicates long-term effectiveness for tafamidis, a kinetic stabilizer approved for the treatment of hereditary TTR amyloidosis. Moreover, we created a predictive model that can be potentially used in the clinical setting to inform patients and clinicians in their therapeutic decisions.Keywords
Funding Information
- National Institutes of Health (DK046335)
- American Heart Association (16PRE31130009)
- Ellen Browning Scripps Foundation (N/A)
This publication has 33 references indexed in Scilit:
- Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathyNeurology, 2018
- Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature GuidelinesAmyloid, 2016
- “Red‐flag” symptom clusters in transthyretin familial amyloid polyneuropathyJournal of the Peripheral Nervous System, 2016
- Repurposing Diflunisal for Familial Amyloid PolyneuropathyJAMA, 2013
- Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences, 2012
- Family Studies of the Genetic Abnormality in Transthyretin (Prealbumin) in Portuguese Patients with Familial Amyloidotic Poly neuropathyaAnnals of the New York Academy of Sciences, 1984
- A PECULIAR FORM OF PERIPHERAL NEUROPATHYBrain, 1952